Novartis drugs fail to help high-risk patients (Reuters)

Reuters – The Novartis diabetes drug Starlix failed to reduce progression to the disease or cut down on serious heart problems in patients at high risk for both diabetes and heart disease, according to a large study released on Sunday.

Related posts:

1. Cholesterol drugs up diabetes risk slightly: study (Reuters)
2. Breastfeeding may curb heart, diabetes risk factors (Reuters)
3. Siblings key in pregnancy-related diabetes risk (Reuters)
4. A1c diabetes test is a better indicator of risk (Reuters)
5. Effects of diet on diabetes risk vary by ethnicity (Reuters)